

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Takashi Shoda, President and Representative Director  
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)  
Please address inquiries to Toshiaki Sai, General Manager,  
Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com/>

## **Notice regarding the acquisition of shares in Zenotech Laboratories Limited**

**Tokyo, January 19, 2009** - Daiichi Sankyo Company, Limited (TSE:4568.jp) ("Daiichi Sankyo") have announced today that the board of Daiichi Sankyo has approved the implementation of an open offer for the acquisition of the common stock of Zenotech Laboratories Limited (BSE:532039) ("Zenotech"). The details are provided below.

### **1. Objective**

In relation to the acquisition of Ranbaxy shares announced in June 2008, and in accordance with the legal requirements in India, Daiichi Sankyo is scheduled to implement an open offer for 20% shares in Zenotech, an affiliate of Ranbaxy. The progress of entire procedure will be announced in due course.

### **2. Outline of Zenotech**

- (1) Trade Name  
Zenotech Laboratories Limited
- (2) Head Office Location  
Hyderabad, India
- (3) Year Incorporated  
2003
- (4) Stock Exchange  
Bombay Stock Exchange (BSE: 532039)
- (5) Number of Employees  
Approximately 160 (including about 50 members in R&D)
- (6) Facilities  
Laboratories: Hyderabad (India), Princeton, NJ (USA)  
Manufacturing: Two facilities
- (7) Business  
Development and manufacturing of biosimilars, oncology and generic injectables

#### **Disclaimer**

Statements contained in this press release regarding the benefits of the acquisition, the business outlook, the demand for the products and services, and all other statements in this release other than recitation of historical facts are forward-looking statements. Words such as "expect", "estimate", "project", "budget", "forecast", "anticipate", "intend", "plan", "may", "will", "could", "should", "believes", "predicts", "potential", "continue", and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, forecasts of market growth, future revenues, benefits of the proposed acquisition, expectations that the acquisition will be accretive to the results, future expectations concerning growth of business, cost competitiveness and expansion of global reach following the acquisition, and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: difficulties encountered in integrating businesses; uncertainties as to the timing of the acquisition; approval of the preferential allotment/transaction by the shareholders of Zenotech; the satisfaction of the closing conditions to the transaction, including the receipt of regulatory approvals; whether certain market segments grow as anticipated; the competitive environment in the pharmaceutical industry and competitive responses to the proposed acquisition; and whether the companies can successfully develop new products and the degree to which these gain market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release.

This document does not constitute an offer to purchase or to sell securities in any jurisdiction.